Citations (38)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Xiao Ding & Feng Ren. (2020) Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-present). Expert Opinion on Therapeutic Patents 30:4, pages 275-286.
Read now
Read now
Jean-Marc Taymans. (2014) Can the increasing number of newly developed leucine-rich repeat kinase 2 inhibitors validate or invalidate a potential disease-modifying therapeutic approach for Parkinson's disease?. Expert Opinion on Therapeutic Patents 24:7, pages 727-730.
Read now
Read now
Raghava R Kethiri & Rajagopal Bakthavatchalam. (2014) Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 – 2013). Expert Opinion on Therapeutic Patents 24:7, pages 745-757.
Read now
Read now
Articles from other publishers (35)
Robert K. Leśniak, R. Jeremy Nichols, Marcus Schonemann, Jing Zhao, Chandresh R. Gajera, Grace Lam, Khanh C. Nguyen, J. William Langston, Mark Smith & Thomas J. Montine. (2022)
Discovery of 1
H-
Pyrazole Biaryl Sulfonamides as Novel G2019S-LRRK2 Kinase Inhibitors
. ACS Medicinal Chemistry Letters 13:6, pages 981-988.
Crossref
Crossref
Sachin Kumar, Tapan Behl, Aayush Sehgal, Sridevi Chigurupati, Sukhbir Singh, Vasudevan Mani, Maha Aldubayan, Ahmed Alhowail, Satvinder Kaur, Saurabh Bhatia, Ahmed Al-Harrasi, Vetriselvan Subramaniyan, Shivkanya Fuloria, Neeraj Kumar Fuloria, Mahendran Sekar & Mohamed M. Abdel Daim. (2022) Exploring the focal role of LRRK2 kinase in Parkinson’s disease. Environmental Science and Pollution Research 29:22, pages 32368-32382.
Crossref
Crossref
Robert K. Leśniak, R. Jeremy Nichols, Marcus Schonemann, Jing Zhao, Chandresh R. Gajera, William L. Fitch, Grace Lam, Khanh C. Nguyen, Mark Smith & Thomas J. Montine. (2022) Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with in vivo efficacy. European Journal of Medicinal Chemistry 229, pages 114080.
Crossref
Crossref
Mitchell H. Keylor, Anmol Gulati, Solomon D. Kattar, Rebecca E. Johnson, Ryan W. Chau, Kaila A. Margrey, Michael J. Ardolino, Cayetana Zarate, Kelsey E. Poremba, Vladimir Simov, Gregori J. Morriello, John J. Acton, Barbara Pio, Xin Yan, Rachel L. Palte, Spencer E. McMinn, Lisa Nogle, Charles A. Lesburg, Donovon Adpressa, Shishi Lin, Santhosh Neelamkavil, Ping Liu, Jing Su, Laxminarayan G. Hegde, Janice D. Woodhouse, Robert Faltus, Tina Xiong, Paul J. Ciaccio, Jennifer Piesvaux, Karin M. Otte, Harold B. Wood, Matthew E. Kennedy, David Jonathan Bennett, Erin F. DiMauro, Matthew J. Fell & Peter H. Fuller. (2021) Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 Inhibitors. Journal of Medicinal Chemistry 65:1, pages 838-856.
Crossref
Crossref
Leah G. Helton, Hardy J. Rideout, Friedrich W. Herberg & Eileen J. Kennedy. (2021)
Leucine rich repeat kinase 2 (
LRRK2
) peptide modulators: Recent advances and future directions
. Peptide Science 114:1.
Crossref
Crossref
Leah G. Helton, Ahmed Soliman, Felix von Zweydorf, Michalis Kentros, Jascha T. Manschwetus, Scotty Hall, Bernd Gilsbach, Franz Y. Ho, Panagiotis S. Athanasopoulos, Ranjan K. Singh, Timothy J. LeClair, Wim Versées, Francesco Raimondi, Friedrich W. Herberg, Christian Johannes Gloeckner, Hardy Rideout, Arjan Kortholt & Eileen J. Kennedy. (2021) Allosteric Inhibition of Parkinson’s-Linked LRRK2 by Constrained Peptides. ACS Chemical Biology 16:11, pages 2326-2338.
Crossref
Crossref
Shuoyan Tan, Xiaoqing Gong, Huanxiang Liu & Xiaojun Yao. (2021) Virtual Screening and Biological Activity Evaluation of New Potent Inhibitors Targeting LRRK2 Kinase Domain. ACS Chemical Neuroscience 12:17, pages 3214-3224.
Crossref
Crossref
Markella Konstantinidou, Asmaa Oun, Pragya Pathak, Bidong Zhang, Zefeng Wang, Frans ter Brake, Amalia M. Dolga, Arjan Kortholt & Alexander Dömling. (2020) The tale of proteolysis targeting chimeras (PROTACs) for Leucine‐Rich Repeat Kinase 2 (LRRK2). ChemMedChem 16:6, pages 959-965.
Crossref
Crossref
C. P. Gonzalez-Hunt, E. A. Thacker, C. M. Toste, S. Boularand, S. Deprets, L. Dubois & L. H. Sanders. (2020) Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson’s disease. Scientific Reports 10:1.
Crossref
Crossref
T. De Wit, V. Baekelandt & E. Lobbestael. (2018) Inhibition of LRRK2 or Casein Kinase 1 Results in LRRK2 Protein Destabilization. Molecular Neurobiology 56:8, pages 5273-5286.
Crossref
Crossref
Charleen T. Chu. (2019) Mechanisms of selective autophagy and mitophagy: Implications for neurodegenerative diseases. Neurobiology of Disease 122, pages 23-34.
Crossref
Crossref
Jie Cao, Yan Zhuang, Juyi Zhang, Zhuwei Zhang, Shuai Yuan, Peng Zhang, Haiying Li, Xiang Li, Haitao Shen, Zhong Wang & Gang Chen. (2018) Leucine-rich repeat kinase 2 aggravates secondary brain injury induced by intracerebral hemorrhage in rats by regulating the P38 MAPK/Drosha pathway. Neurobiology of Disease 119, pages 53-64.
Crossref
Crossref
Tina De Wit, Veerle Baekelandt & Evy Lobbestael. (2018) LRRK2 Phosphorylation: Behind the Scenes. The Neuroscientist 24:5, pages 486-500.
Crossref
Crossref
Sagar S. Bhayye, K. Roy & A. Saha. (2017) Molecular dynamics simulation study reveals polar nature of pathogenic mutations responsible for stabilizing active conformation of kinase domain in leucine-rich repeat kinase II. Structural Chemistry 29:3, pages 657-666.
Crossref
Crossref
Evan H Howlett, Nicholas Jensen, Frances Belmonte, Faria Zafar, Xiaoping Hu, Jillian Kluss, Birgitt Schüle, Brett A Kaufman, J T Greenamyre & Laurie H Sanders. (2017) LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson’s disease. Human Molecular Genetics 26:22, pages 4340-4351.
Crossref
Crossref
Xiao Ding, Xuedong Dai, Kai Long, Cheng Peng, Daniele Andreotti, Paul Bamborough, Andrew J. Eatherton, Colin Edge, Karamjit S. Jandu, Paula L. Nichols, Oliver J. Philps, Luigi Piero Stasi, Zehong Wan, Jia-Ning Xiang, Kelly Dong, Pamela Dossang, Ming-Hsun Ho, Yi Li, Lucy Mensah, Xiaoming Guan, Alastair D. Reith & Feng Ren. (2017) Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors. Bioorganic & Medicinal Chemistry Letters 27:17, pages 4034-4038.
Crossref
Crossref
Emanuela Gancia, Marcel De Groot, Brenda Burton & David E. Clark. (2017) Discovery of LRRK2 inhibitors by using an ensemble of virtual screening methods. Bioorganic & Medicinal Chemistry Letters 27:11, pages 2520-2527.
Crossref
Crossref
K.V. Christensen, G.P. Smith & D.S. Williamson. 2017.
37
80
.
Mark R. Cookson. 2017. Disease-Modifying Targets in Neurodegenerative Disorders. Disease-Modifying Targets in Neurodegenerative Disorders
157
174
.
Nicolas L. Dzamko. 2017. Leucine-Rich Repeat Kinase 2 (LRRK2). Leucine-Rich Repeat Kinase 2 (LRRK2)
123
143
.
E. Lobbestael, L. Civiero, T. De Wit, J.-M. Taymans, E. Greggio & V. Baekelandt. (2016) Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation. Scientific Reports 6:1.
Crossref
Crossref
G. Perera, M. Ranola, D. B. Rowe, G. M. Halliday & N. Dzamko. (2016) Inhibitor treatment of peripheral mononuclear cells from Parkinson’s disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker. Scientific Reports 6:1.
Crossref
Crossref
Melanie Leveridge, Lee Collier, Colin Edge, Phil Hardwicke, Bill Leavens, Steve Ratcliffe, Mike Rees, Luigi Piero Stasi, Alan Nadin & Alastair D. Reith. (2016) A High-Throughput Screen to Identify LRRK2 Kinase Inhibitors for the Treatment of Parkinson’s Disease Using RapidFire Mass Spectrometry. SLAS Discovery 21:2, pages 145-155.
Crossref
Crossref
Katharina E. Rosenbusch & Arjan Kortholt. (2016) Activation Mechanism of LRRK2 and Its Cellular Functions in Parkinson’s Disease. Parkinson's Disease 2016, pages 1-8.
Crossref
Crossref
Anthony A. Estrada & Zachary K. Sweeney. (2015) Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors. Journal of Medicinal Chemistry 58:17, pages 6733-6746.
Crossref
Crossref
N. Dzamko, C.L Geczy & G.M Halliday. (2015) Inflammation is genetically implicated in Parkinson’s disease. Neuroscience 302, pages 89-102.
Crossref
Crossref
Tianxia Li, Xinhua He, Joseph M. Thomas, Dejun Yang, Shijun Zhong, Fengtian Xue & Wanli W. Smith. (2015) A Novel GTP-Binding Inhibitor, FX2149, Attenuates LRRK2 Toxicity in Parkinson’s Disease Models. PLOS ONE 10:3, pages e0122461.
Crossref
Crossref
Dejun Yang, Sharmila Das, Loujing Song, Tianxia Li, Jianqun Yan & Wanli W. Smith. (2015) LDN-73794 Attenuated LRRK2-Induced Degeneration in a <i>Drosophila</i> Parkinson’s Disease Model. Advances in Parkinson's Disease 04:03, pages 49-58.
Crossref
Crossref
Suzanne Lesage. 2015. Movement Disorder Genetics. Movement Disorder Genetics
3
18
.
T. Li, D. Yang, S. Zhong, J. M. Thomas, F. Xue, J. Liu, L. Kong, P. Voulalas, H. E. Hassan, J.-S. Park, A. D. MacKerell & W. W. Smith. (2014) Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models. Human Molecular Genetics 23:23, pages 6212-6222.
Crossref
Crossref
Ralf Heilker, Stefanie Traub, Peter Reinhardt, Hans R. Schöler & Jared Sterneckert. (2014) iPS cell derived neuronal cells for drug discovery. Trends in Pharmacological Sciences 35:10, pages 510-519.
Crossref
Crossref
Sagar S. Bhayye, Kunal Roy & Achintya Saha. (2014) Exploring structural requirement, pharmacophore modeling, and de novo design of LRRK2 inhibitors using homology modeling approach. Medicinal Chemistry Research 23:8, pages 3705-3713.
Crossref
Crossref
Nicolas Dzamko, Jinxia Zhou, Yue Huang & Glenda M. Halliday. (2014) Parkinson’s disease-implicated kinases in the brain; insights into disease pathogenesis. Frontiers in Molecular Neuroscience 7.
Crossref
Crossref
Renée Vancraenenbroeck, Joren De Raeymaecker, Evy Lobbestael, Fangye Gao, Marc De Maeyer, Arnout Voet, Veerle Baekelandt & Jean-Marc Taymans. (2014) In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2. Frontiers in Molecular Neuroscience 7.
Crossref
Crossref
Ralph A Nixon. (2013) The role of autophagy in neurodegenerative disease. Nature Medicine 19:8, pages 983-997.
Crossref
Crossref